Australian regulator sues Pfizer over Lipitor sales tactics


The Australian Competition & Consumer Commision (ACCC) has sued Pfizer (PFE) for the alleged violation of antitrust rules in the marketing of Lipitor.

The ACCC said that prior to the expiry of Lipitor's patent in May 2012, Pfizer offered "significant" discounts and rebates to pharmacies if they stocked at least a year's worth of the cholesterol-lowering treatment.

Lipitor generated annual revenues of over A$700M ($632.35M) in Australia before the drug's IP expired.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs